Search
Menu
Home
HTB
2018
July
11
11 July 2018
Contents
Editorial
11 July 2018: vol 19 no 12: DTG and preconception – special report
Special reports
HIV pipeline 2018: full version
Dolutegravir preconception signal: time is up for shoddy surveillance
Conference reports
AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference
Antiretrovirals
Bictegravir/FTC/TAF (Biktarvy) approved in Europe
Women's health
Dolutegravir: need to consider all pros and cons before switching in pregnancy
Pregnancy
Why U=U does not apply to breastfeeding
PDFs
11 July 2018: vol 19 no 12
HTB RSS
Early access
The RIO study: Q&A about controlling HIV with bNAbs
21 April 2025
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years
20 April 2025
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs
13 April 2025
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
All early access reports
Current issues
April 2025
March 2025
February 2025
Back issues
Special report
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate